Clinical Trials Directory

Trials / Completed

CompletedNCT00544934

Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects

A Dose-ranging Study to Evaluate the Safety, Metabolism and Therapeutic Dosing of Three Multiple Dose Levels of GLY-230 in Healthy and Diabetic Subjects

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Glycadia · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

A dose-ranging study evaluating safety, metabolism and therapeutic dosing of three multiple dose levels of GLY-230 in healthy and diabetic subjects

Conditions

Interventions

TypeNameDescription
DRUGGLY-230125, 250 0r 375 mg bid for 14 days
OTHERPlaceboNo drug administered

Timeline

Start date
2007-02-01
Completion
2007-10-01
First posted
2007-10-16
Last updated
2016-02-10

Source: ClinicalTrials.gov record NCT00544934. Inclusion in this directory is not an endorsement.